Patients with hematopoietic malignancies relapsing after allogeneic hematopoietic SCT (allo-HSCT) have a poor prognosis. We retrospectively analyzed the patients who received azacitidine in our center in the course of treatment of their post-transplant relapse. We identified 31 patients. Relapse occurred at a median of 3.7 (1.7-37.6) months following allo-HSCT. Patients received a median number of three cycles (1-12) of azacitidine (7 days, 75 mg/m 2 daily). Thirty-nine percent of patients had either a monosomal karyotype or a complex karyotype. Eleven patients (35%) received at least one DLI. Eleven patients responded to azacitidine, with four patients achieving a CR (13%). Median time to best response was 92 (35-247) days, with a median duration of 209 (64-751) days. One-year estimated survival rate was 14%. In conclusion, azacitidine may reinduce durable remissions in very few patients with AML or myelodysplastic syndrome. The toxicity related to azacitidine was high, although it may be difficult to distinguish between treatment-related side effects, namely due to cytopenia and toxicity due to the relapse or disease progression itself. Early administration of azacitidine after transplant followed by DLI should be considered as a pre-emptive therapy for potential relapse in patients with minimal residual disease or high-risk myeloid malignancies.
INTRODUCTION
Relapse after allogeneic hematopoietic SCT (allo-HSCT) for AML, myelodysplastic syndrome (MDS) or myeloproliferative neoplasm remains the main cause of treatment failure and is associated with a very poor prognosis and a short survival. 1, 2 Reductions of immunosuppressive therapy, chemotherapy with or without infusion of DLI or second allo-HSCT are regularly proposed, but results remain disappointing. [3] [4] [5] Azacitidine (AZA), a DNA-hypomethylating agent with a relatively low toxicity profile, emerged in the recent years as an attractive treatment modality in patients with myeloid malignancies who are not eligible to intensive chemotherapy. [6] [7] [8] The exact mechanism of action of AZA is still debated. However, different studies suggested an immunomodulatory effect of the drug. 9 AZA has been shown to increase the expression of tumor Ags by leukemic cells. [10] [11] [12] [13] AZA can also increase regulatory T cells and CD8 þ tumor-specific T-cell responses both in vitro and in the human clinical setting. 14, 15 Thus, AZA administration may potentially enhance the GVL effect while reducing active GVHD. 16 This report analyzed the outcome of 31 patients who were treated with standard dose of AZA as salvage therapy after relapse of their myeloid malignancy following allo-HSCT.
PATIENTS AND METHODS

Study designs
This single center retrospective analysis was performed at the University Hospital of Nantes (Nantes, France). Between September 2006 and July 2013, 31 patients were treated with AZA for relapse of their myeloid malignancy following allo-HSCT. As per institutional guidelines, patients received AZA after relapse irrespective of donor type, stem cell source or type of conditioning regimen. The study was conducted according to the Declaration of Helsinki Principles. For the purpose of this analysis, data were updated as of 1 November 2012.
According to the drug label, 75 mg/m 2 AZA was administered subcutaneously for 7 consecutive days every 4 weeks (cycle: day 1 ¼ day 28). Immunosuppressive drugs were discontinued before AZA therapy initiation.
Monitoring of efficacy
Hematologic relapse after allo-HSCT was defined according to standard practice. Response to AZA therapy was defined as stable disease (temporary disease control defined by no increasing blastosis and stable chimerism), PR or CR (BM involvement with o5% blasts or normalization of blood counts). 17 Disease response was assessed at the beginning of each AZA cycle and in the case of toxicity or when progressive disease was suspected.
Monitoring of toxicity
The toxicity was assessed at least once a month and scored according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, 2009.
Statistical analysis
Median survival and overall survival (OS) were estimated from the date of the relapse using the Kaplan-Meier method. Differences in OS were studied by univariate analysis, using the log-rank test and Cox regression. 
RESULTS
Patient characteristics
Patients' characteristics are summarized in Table 1 . Median age at the time of allo-HSCT was 57 (range, 17-69) years. Diagnoses included de novo AML (n ¼ 13), secondary AML (n ¼ 6, 1 therapy related and 5 secondary to MDS or myeloproliferative neoplasms), MDS (n ¼ 11) and one MPN. Eleven (35%) patients had a poor prognosis associated with abnormal karyotypes, either monosomal (n ¼ 3, 10%) or complex (n ¼ 9, 29%). Before allo-HSCT, 19 patients (61%) were in CR (15 CR1 and 4 CR2), 4 received (13%) upfront allo-HSCT without previous chemotherapy and 8 patients (26%) were refractory to induction chemotherapy or had progressive disease. Relapse occurred at a median of 3.7 (1.7-37.6) months following allo-HSCT.
After allo-HSCT, 9 patients (29%) experienced acute GVHD (seven grade 1 and two grade 2 cases). In all cases, GVHD was resolved at the time of relapse; moreover, discontinuation of immunosuppressive drugs at relapse was not associated with a flare-up of GVHD.
Relapse therapy In this series, 12 patients received another salvage therapy before receiving AZA and DLI: low-dose subcutaneous cytarabine (n ¼ 1), radiotherapy on sites of extramedullary relapse (n ¼ 1), pegylated IFNa-2a (n ¼ 2), sorafenib (n ¼ 1) and hydroxyurea (n ¼ 7). While on treatment with AZA, eight patients received valproic acid (500 mg three times daily) and all-trans retinoic acid (45 mg/m 2 ).
AZA administration and toxicity AZA was administered for a median of three cycles (range, 1-12), at a dose of 75 mg/m 2 per day for 7 days every 4 weeks for the majority of the patients (92%). AZA dose was reduced to 60 mg/m 2 per day (two patients) for 7 days according to the attending physician because of fear of toxicity. No dose reduction was performed for grade 1 or 2 toxicities. Treatment was discontinued in case of grade 3 or 4 toxicity. The overall toxicity rate was 62%, with grade 1-4 toxicities observed in 10%, 19%, 13% and 23% of patients, respectively (Table 2) . Twelve patients (38%) had to be readmitted to hospital owing to treatment toxicities, with the main reasons being fever, sepsis or aplasia. There was no difference in the incidence of toxicities between AZA responders and non-responders (Fisher's exact test, P ¼ 0.70). In a single patient, severe sepsis leads to multiorgan failure and death. Death was owing to disease progression in 11 cases.
DLI
In those patients who did not develop GHVD, serious infection or progressive disease, at least one DLI was administered to enhance the GVL effect: 12 patients received at least one DLI and a total of 16 DLI were infused for a total of 106 courses of AZA. Seven patients received DLI before the first AZA cycle, six patients received DLI between AZA cycles and one patient received DLI after completion of seven AZA cycles. Two patients received lymphodepletion before DLI using fludarabine for one patient and CY for another patient. This last patient developed cutaneous grade 2 acute GVHD 8 days following DLI. 18 After failure of AZA therapy, other treatments (hydroxyurea (n ¼ 2), amsacrine (n ¼ 2), intensive chemotherapy (n ¼ 2) and a second allo-HSCT (n ¼ 1)) were given without improvement.
Disease response and survival With a median follow-up of 30 (range, 3.8-51) months, 11 of 31 patients could achieve an objective response (35%): four CR (14%) and seven stable disease (22%). The median time to best response was 92 (range, 35-247) days with a median PFS of 361 (range, 64-751) days. The median OS from relapse was 153 (range, 39-928) days (Figure 1a) . At last follow-up, three patients were still alive with a median follow-up of 590 days, with two patients being disease free and still receiving AZA with a persistent CR.
In univariate analysis, response to AZA was found to be associated with an improved OS (median OS, 308 vs 108 days, Po0.005; Figure 1b) , while a monosomal or complex karyotype had a worse outcome (118 days with a monosomal karyotype vs 186 days without (P ¼ 0.02); 105 days with complex karyotype vs 196 days without (P ¼ 0.004); Table 3 ). Other parameters such as age, gender, use of DLI or other specific therapeutic agent were not found to be significantly associated with outcome. Time from allo-HSCT to relapse was not found to be associated with the response to AZA by logistic regression (P ¼ 0.36), and did not correlate with OS by Cox regression (P ¼ 0.24). Status before allo-HSCT was not associated with rate of response to AZA (31% and 55% for patients being in CR or progressive disease before allo-HSCT, respectively, P ¼ 0.41).
Chimerism
Chimerism was monitored following AZA treatment in only 15 patients. Three patients had an improvement of their chimerism on selected CD3 þ cells. In two of them, this improvement occurred following DLI, while one patient improved its chimerism from 57 to 89% with AZA only without obtaining remission.
DISCUSSION
As reported by Kim et al. 19 and Damaj et al., 20 AZA has proven to be an effective treatment in serving as a bridge to allo-HSCT. However, disease relapse following allo-HSCT remains challenging 21 and current attempts to treat these patients are still disappointing. Retrospective analyses of AZA given at various doses and schedules for post-transplant relapse of AML and/or MDS have reported a response rate ranging from 55 to 72%, but with a poor survival ranging from 16 to 23% at 2 years. [22] [23] [24] [25] Recently, Schroeder et al. 26 conducted a prospective trial to evaluate the efficacy of AZA (100 mg/m 2 per day for 5 days) combined to DLI as first salvage therapy for relapse of AML or MDS after allo-HSCT. Seventy-three percent of the patients could receive DLI. Disease response was achieved in 30% of cases with 23% of CRs, and 17% of patients remained in CR for a median time of 26 months.
In the current report, AZA was not used as first-line salvage therapy in 39% of patients. However, 38% of the patients responded, while only 15% achieved a CR, in line with the results from Schroeder et al. 26 The OS rates at 1 and 2 years were, respectively, 25% and 5%. These modest results were achieved at the cost of a relatively high rate of toxicity with 56% of patients experiencing a grade 3 or 4 toxicity. However, one must acknowledge that it is difficult to distinguish between drugrelated toxicity and complications arising from disease progression in such heavily pretreated patients. In conclusion, AZA used as salvage therapy may allow induction of remission in a limited number of AML or MDS patients relapsing after allo-HSCT. AZA-related toxicity in this setting was relatively high. Most patients (if not all) will progress after AZA, even those patients who could achieve an initial response. Early administration of AZA after transplant may allow to improve these results as suggested by Platzbecker et al., 27 who have shown that preemptive AZA therapy rather than salvage therapy could delay hematological relapse. With this background, we are currently conducting a prospective trial using the combination of early preemptive administration of AZA followed by DLI in high-risk myeloid malignancies.
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